0
Startups & Venture·August 29, 2026·1 min read

“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Share

A veteran of a $4B biotech franchise choosing a smaller, AI-native fund is another data point that biology is moving from hit-driven discovery to engineered, model-driven pipelines. If you’re building in bio, assume diligence will focus less on narrative and more on how your data, models, and trial design compress time and cost in a system that still makes clinical validation brutally expensive.

Startups & Venture

Minneapolis-based Yardstik, a provider of workforce monitoring tech, raised a $30M Series B led by Harbert Growth Partners, taking its total funding to $65M

Fresh $30M into Yardstik for ongoing fraud and risk monitoring shows background checks are shifting from point-in-time to continuous surveillance of employees and contractors. If you rely on distributed or gig labor, expect rising pressure—from insurers, partners, or boards—to plug into this kind of telemetry and be ready to answer for privacy and governance choices.

Startups & Venture

Metriport, whose tools help doctors retrieve patient data, raised $26M in Series A and seed funding led by Matrix GP TJ Parker, taking its total raise to $28.4M

Healthcare data plumbing is getting venture-scale attention again—$26M into retrieval tooling is a bet that interoperability friction is now the main blocker, not model capability. If you build in or sell to healthcare, assume patient data access will get easier over the next 12–24 months and design your product and integrations for that world, not the current mess.